BTD Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the human A-549 lung adenocarcinoma cell line, featuring targeted disruption of the BTD gene. This knockout model offers a loss-of-function system suitable for investigating biotin-dependent metabolic pathways in an epithelial context. The polyclonal format provides a heterogeneous pool of edited cells, maintaining cellular diversity while enabling robust functional analysis of BTD under controlled experimental conditions.
The parental A-549 cell line originates from lung adenocarcinoma tissue of a Caucasian male and serves as a well-established model for alveolar type II epithelium. These cells display characteristic epithelial morphology, synthesize surfactant components, and exhibit reliable growth in vitro. A-549 is widely utilized in respiratory disease research, cancer biology, and drug metabolism studies due to its thoroughly documented phenotype and reproducible behavior in cell-based assays.
The BTD gene encodes biotinidase, the enzyme responsible for hydrolyzing biocytin and biotinyl-peptides to release free biotin. Free biotin acts as an essential cofactor for biotin-dependent carboxylases, including acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, and 3-methylcrotonyl-CoA carboxylase, which are critical for fatty acid synthesis, gluconeogenesis, and branched-chain amino acid catabolism. Biotinidase functions upstream of holocarboxylase synthetase (HLCS) and interacts with the biotin transporter SLC5A6 to maintain cellular biotin homeostasis. Disruption of BTD impairs biotin recycling, leading to reduced holocarboxylase formation and subsequent metabolic dysfunction.
Within the A-549 lung adenocarcinoma background, BTD knockout enables dissection of biotin-mediated metabolic processes relevant to cancer cell proliferation and survival. Lung tumor cells often exhibit altered metabolic dependencies, and biotin availability may influence energy metabolism and macromolecule biosynthesis. This model allows researchers to assess how loss of biotinidase activity affects biotin-dependent carboxylase function, cellular bioenergetics, and growth phenotypes under various nutrient conditions. Additionally, the knockout recapitulates molecular features of biotinidase deficiency and multiple carboxylase deficiency, providing a platform to study disease mechanisms in an epithelial setting.
Research applications for these polyclonal knockout cells include quantitative analysis of target gene disruption via RT-qPCR and western blotting, measurement of biotinidase enzyme activity, and downstream carboxylase activity assays such as acetyl-CoA carboxylase activity. Cell-based assays can monitor proliferation, metabolic flux, and responses to biotin-depleted or biotin-supplemented media. The population is well-suited for drug screening targeting biotin-dependent pathways and for metabolic profiling to identify novel vulnerabilities in lung adenocarcinoma. For further technical details and ordering information, please contact Ascent Research.
